Eli Lilly and Company $LLY Position Boosted by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,307 shares of the company’s stock after acquiring an additional 645 shares during the period. Eli Lilly and Company comprises 1.4% of Teamwork Financial Advisors LLC’s portfolio, making the stock its 25th largest holding. Teamwork Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $13,083,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Abel Hall LLC raised its stake in Eli Lilly and Company by 1.4% in the 3rd quarter. Abel Hall LLC now owns 2,713 shares of the company’s stock valued at $3,139,000 after purchasing an additional 38 shares during the last quarter. James Hambro & Partners LLP boosted its stake in shares of Eli Lilly and Company by 38.3% during the 3rd quarter. James Hambro & Partners LLP now owns 1,831 shares of the company’s stock worth $2,123,000 after purchasing an additional 507 shares during the last quarter. Richards Merrill & Peterson Inc. boosted its stake in shares of Eli Lilly and Company by 8.6% during the 3rd quarter. Richards Merrill & Peterson Inc. now owns 1,255 shares of the company’s stock worth $1,452,000 after purchasing an additional 99 shares during the last quarter. New Wave Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 3.5% during the third quarter. New Wave Wealth Advisors LLC now owns 2,511 shares of the company’s stock worth $2,929,000 after buying an additional 84 shares in the last quarter. Finally, Talbot Financial LLC grew its holdings in shares of Eli Lilly and Company by 0.3% during the third quarter. Talbot Financial LLC now owns 37,225 shares of the company’s stock worth $43,072,000 after buying an additional 119 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on LLY. Sanford C. Bernstein boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Cantor Fitzgerald lifted their target price on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research note on Thursday, October 8th. Truist Financial boosted their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Trading Down 1.1%

NYSE LLY opened at $1,242.76 on Tuesday. Eli Lilly and Company has a 12 month low of $793.82 and a 12 month high of $1,292.65. The company has a 50-day moving average of $1,180.34 and a 200-day moving average of $1,111.84. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a market cap of $1.17 trillion, a P/E ratio of 41.70, a P/E/G ratio of 1.67 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same period last year, the company earned $6.31 earnings per share. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 33.56 earnings per share for the current year.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Omvoh delivered positive pediatric trial results. In the Phase 3 SHINE-2 study, 81% of children with moderately to severely active ulcerative colitis achieved a clinical response after induction, while half of responders reached clinical remission after one year. Lilly plans to submit the data to regulators for a potential pediatric label expansion. Lilly Omvoh pediatric ulcerative colitis trial results
• Positive Sentiment: Foundayo and the broader GLP-1 franchise remain key growth drivers. European regulators recommended approval of Lilly’s oral weight-loss treatment Foundayo, while analysts expect it to continue gaining market share. Strong GLP-1 sales are also expected to support upcoming third-quarter results. European Union regulators recommend Foundayo approval
• Positive Sentiment: Lilly expanded its drug-delivery capabilities. The company signed a collaboration with Metis TechBio valued at up to $1.1 billion, potentially accelerating development of AI-enabled drug-delivery technology. Metis TechBio drug-delivery collaboration
• Neutral Sentiment: Lilly will present updates on several oncology candidates at the ESMO Congress, including treatments targeting ovarian, lung, thyroid and breast cancers. The data could broaden the company’s growth base, although the commercial impact remains dependent on clinical and regulatory outcomes. Lilly oncology pipeline ESMO update
• Negative Sentiment: Competition, valuation and legal exposure are weighing on sentiment. Investors are monitoring a potential GLP-1 price war with Novo Nordisk and Lilly’s dependence on a concentrated weight-loss portfolio. A Pennsylvania lawsuit also alleges that insulin manufacturers and pharmacy-benefit managers inflated insulin prices, adding regulatory and reputational risk. Eli Lilly insulin pricing lawsuit

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.